Company Overview - Kangtuo Medical, established on March 14, 2005, is located in Xi'an, Shaanxi Province, and was listed on May 18, 2021. The company specializes in the research, production, and sales of three types of implantable medical devices [1] - The company's main business revenue composition includes: PEEK material neurosurgical products (63.86%), titanium material neurosurgical products (22.54%), other products (10.97%), and supplementary products (2.62%) [1] Stock Performance - On September 3, Kangtuo Medical's stock rose by 5.04%, reaching a price of 38.16 CNY per share, with a trading volume of 71.24 million CNY and a turnover rate of 2.36%. The total market capitalization is 3.1 billion CNY [1] Fund Holdings - Dongxing Fund has a significant holding in Kangtuo Medical, with its Dongxing Pharmaceutical Biotechnology Quantitative Selection Mixed A Fund (020830) holding 6,653 shares, accounting for 3.51% of the fund's net value, making it the sixth-largest holding [2] - The fund has achieved a year-to-date return of 36.69%, ranking 1474 out of 8180 in its category, and a cumulative return of 29.01% since its inception [2] Fund Manager Profile - The fund manager of Dongxing Pharmaceutical Biotechnology Quantitative Selection Mixed A Fund is Li Bingwei, who has been in the position for 9 years and 85 days. The total asset size of the fund is 352 million CNY, with the best return during his tenure being 62.49% and the worst being -11.19% [3]

Core Viewpoint - The company plans to distribute a cash dividend of 2 RMB per 10 shares (including tax) to all shareholders, subject to approval at the upcoming shareholder meeting [1][2]. Summary by Sections Profit Distribution Plan - As of June 30, 2025, the company's undistributed profits amount to RMB 67.5 million, and the proposed cash dividend represents 29.54% of the net profit attributable to shareholders for the first half of 2025 [1]. Decision-Making Process - The company's board of directors approved the profit distribution proposal on August 27, 2025, with a unanimous vote of 9 in favor. This proposal will be submitted for approval at the 2025 second extraordinary general meeting of shareholders [2]. Adjustments for Changes in Share Capital - If there are changes in the total share capital due to convertible bonds, share buybacks, or other corporate actions before the record date, the total distribution amount will remain unchanged, but the per-share distribution will be adjusted accordingly [2].

证券代码：688314 证券简称：康拓医疗 公告编号：2025-036 西安康拓医疗技术股份有限公司 关于召开2025年第二次临时股东会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 股东会召开日期：2025年9月16日 ? 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统 一、 召开会议的基本情况 （一） 股东会类型和届次 （二） 股东会召集人：董事会 （三） 投票方式：本次股东会所采用的表决方式是现场投票和网络投票相 结合的方式 （四） 现场会议召开的日期、时间和地点 召开日期时间：2025 年 9 月 16 日 14 点 00 分 召开地点：西安市高新区毕原一路西段 1451 号西安康拓医疗技术股份有限 公司三楼会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2025 年 9 月 16 日 至2025 年 9 月 16 日 A 股股东 非累积投票议案 本次提交股东会审议的议案已经公司第二届董事会第十八次会 ...

Core Viewpoint - Xi'an Kontour Medical Technology Co., Ltd. reported a revenue increase of 11.07% and a net profit increase of 12.72% for the first half of 2025, indicating strong growth in the medical device sector, particularly in neurosurgery and PEEK material products [1][14]. Company Overview and Financial Indicators - The company specializes in the research, production, and sales of Class III implantable medical devices, focusing on neurosurgery, thoracic surgery, and oral surgery [5][13]. - As of June 30, 2025, the company reported total assets of RMB 778.07 million, with a net asset value of RMB 680.69 million, reflecting a year-on-year increase of 4.13% and 7.10% respectively [3][14]. - The company achieved a total revenue of RMB 170.32 million and a total profit of RMB 65.36 million for the first half of 2025 [3][14]. Industry Context - The company operates within the specialized equipment manufacturing industry, specifically in the biomedical engineering sector, which is experiencing growth due to aging populations and increasing health demands [14]. - The implementation of centralized procurement policies is driving the clinical penetration of high-value medical consumables, benefiting companies like Kontour Medical [14][15]. Business Performance - The neurosurgery segment generated RMB 149.04 million in revenue, a 12.01% increase from the previous year, with PEEK material products contributing RMB 108.77 million, up 13.05% [14][15]. - The thoracic surgery segment reported revenue of RMB 1.17 million, with PEEK material products showing a 20.28% increase [15]. - The company has successfully expanded its market presence in the facial reconstruction sector, achieving RMB 5.06 million in revenue, a significant increase from the previous year [17]. Product Development and Innovation - The company holds 20 Class III implantable medical device registrations, with PEEK material products leading the domestic market [5][13]. - Ongoing research projects include the development of personalized PEEK facial implants and absorbable membranes, aimed at enhancing patient recovery and surgical outcomes [18]. - The company has initiated the production of PEEK bone plates in the U.S. and is expanding its product offerings in international markets [15][18]. Market Position - Kontour Medical maintains the largest market share in the domestic PEEK material cranial repair and fixation products, positioning itself as a leader in the neurosurgical implant sector [13][14]. - The company is leveraging its technological advantages to accelerate the replacement of traditional titanium materials with innovative PEEK solutions [14][15].

Core Viewpoint - Xi'an Kontuo Medical Technology Co., Ltd. reported a positive financial performance for the first half of 2025, with significant increases in revenue and net profit, alongside a planned cash dividend distribution to shareholders [1]. Financial Performance - Total assets as of the end of the reporting period amounted to ¥778,070,632.43, reflecting a 4.13% increase from the previous year [3]. - The net assets attributable to shareholders reached ¥680,693,200.44, up 7.10% compared to the previous year [3]. - Operating revenue for the period was ¥170,316,349.76, representing an 11.07% increase year-on-year [3]. - Total profit for the period was ¥65,359,324.72, which is a 10.27% increase from the previous year [3]. - Net profit attributable to shareholders was ¥54,998,635.19, marking a 12.72% increase compared to the same period last year [3]. - The basic earnings per share were ¥0.68, up 13.33% from ¥0.60 in the previous year [3]. Dividend Distribution - The company plans to distribute a cash dividend of ¥2 per 10 shares (including tax) to all shareholders, amounting to a total of ¥16,247,834.40 based on the total share capital of 81,239,172 shares [1].

Core Insights - 康拓医疗 reported a revenue of 170 million yuan for the first half of 2025, representing a year-on-year growth of 11.07% [1] - The company's net profit attributable to shareholders reached approximately 54.99 million yuan, marking a year-on-year increase of 12.72% [1] - The non-recurring net profit was about 50.39 million yuan, showing a significant year-on-year growth of 25.02% [1] - Basic earnings per share stood at 0.68 yuan [1] - The company proposed a cash dividend of 2 yuan (including tax) for every 10 shares to all shareholders [1]

Group 1 - Company announced the acquisition of approximately 55.50% equity in Xi'an Salamander Biotechnology Co., Ltd. and about 72.99% of the property interests in Xi'an Huicai Enterprise Management Consulting Partnership for a total price of approximately 84.98 million RMB [1] - Following the transaction, the company and its newly established wholly-owned subsidiary will directly hold 63.0001% of Salamander Biotechnology's equity and indirectly hold 27.0074% through Huicai, resulting in a total ownership of 90.0075% [1] - Salamander Biotechnology will become a subsidiary of the company and will be included in the consolidated financial statements [1] Group 2 - As of the report date, the company's market capitalization is 3 billion RMB [2] - The company's revenue composition for the year 2024 is projected to be 96.82% from medical device manufacturing and 3.18% from other businesses [1]

西安康拓医疗技术股份有限公司 证券代码：688314 证券简称：康拓医疗 公告编号：2025-036 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统 一、 召开会议的基本情况 （一） 股东会类型和届次 2025年第二次临时股东会 （二） 股东会召集人：董事会 （三） 投票方式：本次股东会所采用的表决方式是现场投票和网络投票相 结合的方式 （四） 现场会议召开的日期、时间和地点 关于召开2025年第二次临时股东会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 股东会召开日期：2025年9月16日 召开日期时间：2025 年 9 月 16 日 14 点 00 分 召开地点：西安市高新区毕原一路西段 1451 号西安康拓医疗技术股份有限 公司三楼会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2025 年 9 月 16 日 至2025 年 9 月 16 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间 ...

每股分配比例：每 10 股派发现金红利 2 元（含税） 本次利润分配以实施权益分派股权登记日登记的总股本为基数，具体 日期将在权益分派实施公告中明确。 在实施权益分派的股权登记日前西安康拓医疗技术股份有限公司（以 下简称"公司"）总股本发生变动的，拟维持分配总额不变，相应调整每股分配 比例，并将另行公告具体调整情况。 本次利润分配方案尚需提交公司 2025 年第二次临时股东会审议，审议 通过之后方可实施。 证券代码：688314 证券简称：康拓医疗 公告编号：2025-032 西安康拓医疗技术股份有限公司 关于 2025 年半年度利润分配方案公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次利润分配方案尚需提交公司 2025 年第二次临时股东会审议，审议通过 之后方可实施。 二、 公司履行的决策程序 公司于 2025 年 8 月 27 日召开第二届董事会第十八次董事会，以 9 票同意、 0 票反对、0 票弃权审议通过了《关于公司 2025 年半年度利润分配预案的议案》。 董事会同意本次利润分配预案，并同 ...

Core Insights - The company reported a revenue of 170 million yuan for the first half of 2025, representing a year-on-year growth of 11.07% [1] - The net profit attributable to shareholders reached approximately 54.99 million yuan, marking a year-on-year increase of 12.72% [1] - The net profit after deducting non-recurring gains and losses was about 50.39 million yuan, showing a significant year-on-year growth of 25.02% [1] - The basic earnings per share stood at 0.68 yuan [1] - The company plans to distribute a cash dividend of 2 yuan (including tax) for every 10 shares to all shareholders [1]